Market Newsdesk

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) — Researchers at the University South Florida in Tampa have received a $44.4 million grant from the National Institutes of Health (NIH) for the Preventing Alzheimer’s with Cognitive Training (PACT) Study. This new grant furthers prior research, published as findings of the ACTIVE Study in 2017, that showed a small amount of cognitive training significantly reduced the risk and incidence of dementia among older adults. The computerized brain training used in the prior study and the new study is found exclusively in the BrainHQ app, made by Posit Science, and is based on the science of brain plasticity – how the brain rewires itself through learning.

The PACT Study is a very large randomized controlled trial, which plans to enroll 7,600 adults, aged 65 and older, to test the effectiveness of BrainHQ computerized brain exercises in reducing the incidence of medical diagnoses of Mild Cognitive Impairment (MCI) and dementia.

A feasibility stage of the study with over 1,000 participants has been completed, and the new grant, to be overseen by the National Institute on Aging, will be deployed to bring the study to scale, with a completion target date in 2027.

PACT participants will be randomized into two training groups. Each group will be asked to complete a total of 25 hours over the course of up to five months, and then an additional 10 hours after one year and two years.

“This study addresses the central question that most people have about brain training – does training your brain reduce your chances of dementia?” said Dr. Henry Mahncke, CEO of Posit Science, the maker of BrainHQ.

The ACTIVE study provided the possible beginnings of an answer in 2017. Those results grabbed headlines worldwide, since it was the first large randomized controlled trial to show an intervention (of any kind) could be effective in reducing dementia risk and incidence. Researchers reported an up to 48 percent reduction in dementia incidence among people who asked to complete up to 18 hours of training and an overall 29 percent reduction in dementia risk.

A 2020 study in Australia also found a statistically and clinically significant reduction in Alzheimer’s risk from an intervention that combined advice on Alzheimer’s risk reduction with using BrainHQ over an eight-week period, a meeting with a dietician to set up a diet plan, and a meeting with a physiologist to set up a physical exercise plan, when compared to a control group just getting advice on lifestyle risk redaction, brain exercise, diet, and physical exercise.

Some eighteen studies have been published on the impact of using BrainHQ among people with MCI or similar pre-dementia conditions, who are typically considered at elevated risk for Alzheimer’s or other dementias. Results from those studies have included improved performance on standard measures of cognitive abilities, better performance on standard measures of mood, better performance at tasks necessary to maintain independent living, better connectivity in key cortical networks, and improvement in the autonomic nervous system (as measured by heart rate variability).

“It’s gratifying to see the NIH going the distance – building on the established science of brain training to answer the crucial question of dementia prevention,” Dr. Mahncke observed. “Billions have been spent in the thus far unsuccessful search for drugs to prevent MCI and dementia, and so it’s great to see a serious commitment to evaluating the plasticity-based training that has delivered so many promising results in recent studies. It’s impressive that USF is leading this study – they have a strong history of performing large-scale clinical trials required to advance basic science into clinical practice.”

More than 100 published studies of the exercises in BrainHQ have shown benefits, including gains in standard measures of cognition (attention, speed, memory, executive function), in standard measures of quality of life (mood, confidence and control, managing stress, health-related quality of life) and in real world activities (gait, balance, driving, everyday cognition, maintaining independence, healthcare costs). BrainHQ is now offered, without charge, as a benefit by leading national and 5-star Medicare Advantage plans and by hundreds of clinics, libraries, and communities. Consumers can also try BrainHQ for free at http://www.brainhq.com.

Contact: [email protected]

FORT LAUDERDALE, Fla., April 06, 2021 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for a version of the Pure-Vu® System that is compatible with gastroscopes used during upper gastrointestinal (GI) endoscopy procedures to remove blood, blood clots and debris in order to provide a clear field-of-view for the endoscopist. The device is designed to integrate with therapeutic gastroscopes to enable safe and rapid cleansing during the procedure, while preserving established procedural workflow and techniques.

“We are excited to announce the filing of the 510(k) with the FDA for our new Pure-Vu System compatible with gastroscopes used during upper GI endoscopies. Our potential entry into the upper GI market is a natural next step in our growth strategy for the Pure-Vu System. If approved, this product will expand our total addressable market, and we see potential synergies for our commercial team as we intend to target the same population of GI physicians,” stated Tim Moran, Chief Executive Officer of Motus GI. “Launching a version of Pure-Vu designed for use during upper GI endoscopy is the result of collaboration between our R&D team working directly with key physicians using the Pure-Vu System who saw the potential for leveraging our technology for another significant unmet need in the GI space.”

Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc. The mortality rate of this condition can reach up to approximately 10%, as noted in Thad Wilkins, MD, et al., American Family Physician (2012). Removing adherent blood clots from the field of view is a significant need in allowing the physician the ability to identify and treat the bleed source.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks related to the Company’s cost reduction plan, the cost savings and the cash expenses related to the implementation of the plan, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 16, 2021, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:


Bob Yedid
LifeSci Advisors
(646) 597-6989
[email protected]

VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) — Canterra Minerals Corporation (TSXV:CTM) (OTCQB: CTMCF) (“Canterra” or the “Company”) is pleased to announce the appointment of Asa East, B.Sc., to the position of Vice President, Exploration (“VPx”), bolstering its highly experienced technical team.

Mr. East is an exploration geologist with over 15 years mineral exploration experience throughout the North American Cordillera, Western Africa, and Far East Russian Gold Districts. Mr. East has spent the last 11 years in various positions with Kinross Gold Corporation at several of its regions and mine sites across the globe, most recently serving as Director of Exploration for North America. During his tenure with Kinross, Mr. East contributed to several resource growth projects and generative exploration initiatives that have added significant value to the mine life at multiple operations. Prior to joining Kinross, Mr. East worked with Underworld Resources Inc, as part of the team that discovered the Golden Saddle Resource, which was subsequently sold to Kinross in 2010. During his career, Mr. East has managed technical activities on a variety of deposit types and geologic terranes, developing a strong technical understanding of orogenic, epithermal, intrusion related, and Carlin type gold systems.

“Asa brings a wealth of gold exploration experience from across the globe in every type of gold deposit setting and has been successful in adding resources and reserves and making discoveries from Russia to Ghana to Nevada. We are very excited to have him join the Canterra team and begin leading the summer exploration program on the Wilding Gold Project on the island of Newfoundland,” stated Chris Pennimpede, President & CEO of Canterra.

About Canterra Minerals

Canterra is earning a 100% interest in the Wilding and Noel Paul Gold Projects, located 50km south, by logging road, from Millertown and directly northeast of Marathon Gold’s Valentine Lake Gold Project in Central Newfoundland. The 236km² property package includes 50km of the northeastern strike-extension of the Rogerson Lake Structural Corridor, which hosts Marathon Gold’s Valentine Lake deposits, Matador Mining’s Cape Ray deposit, Sokoman’s Moosehead discovery and Tru Precious Metals’ Golden Rose and Twilight discoveries. A $2.75 million exploration program is underway, focusing on drilling and surface exploration on the Wilding Gold Project. This program will include additional diamond drilling on the existing zones and follow up trenching and diamond drilling on numerous targets identified from previous soil geochemistry sampling. Canterra’s team has more than 100 years of experience searching for gold and diamonds in Canada and have been involved in the discovery of the Snap Lake diamond mine, in addition to the discovery of the Blackwater Gold deposit in British Columbia, Canada.

ON BEHALF OF THE BOARD OF CANTERRA MINERALS CORPORATION

Chris Pennimpede

President & CEO

Additional information about the Company is available at www.canterraminerals.com
For further information, please contact: +1 (604) 687-6644
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements that constitute “forward-looking information” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the TSX Venture Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include risks associated possible accidents and other risks associated with mineral exploration operations, the risk that the Company will encounter unanticipated geological factors, the possibility that the Company may not be able to secure permitting and other governmental clearances necessary to carry out the Company’s exploration plans, the risk that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere with the Company’s business and prospects.; the business and operations of the Company; unprecedented market and economic risks associated with current unprecedented market and economic circumstances due to the COVID-19 pandemic, as well as those risks and uncertainties identified and reported in the Company’s public filings under its respective SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 20^th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 9:30 a.m. Eastern Time.

Event:	20th Annual Needham Virtual Healthcare Conference
Date:	April 13, 2021
Format:	Fireside chat & 1:1 Investor meetings
Time:	9:30 a.m. ET

A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/. Replay of the webcast will be archived on the Company’s website for 90 days following the event.

Esperion Therapeutics

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.

Esperion Therapeutics’ Commitment to Patients with Hyperlipidemia

High levels of LDL-C can lead to a build-up of fat and cholesterol in and on artery walls (known as atherosclerosis), potentially leading to cardiovascular events, including heart attack and stroke. In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C. There are approximately 18 million people in the U.S. living with elevated levels of LDL-C despite taking maximally tolerated lipid-modifying therapy — including individuals considered statin averse — leaving them at high risk for cardiovascular events¹. In the United States, more than 50 percent of atherosclerotic cardiovascular disease (ASCVD) patients and heterozygous familial hypercholesterolemia (HeFH) patients who are not able to reach their guideline recommended LDL-C levels with statins alone need less than a 40 percent reduction to reach their LDL-C threshold goal².

Esperion’s mission as the Lipid Management Company is to deliver oral, once-daily medicines that complement existing oral drugs to provide the additional LDL-C lowering that these patients need.

References

<sup>(1
)  Esperion
market research on file: research project interviewing 350 physicians. Esperion Therapeutics, Inc. Sept-Oct 2018.

(2
)  Data
on file: analysis of NHANES database. Esperion Therapeutics, Inc. 2018.</sup>

Investor Contact:
Kaitlyn Brosco
Esperion
[email protected]

 

AUSTIN, Texas, April 06, 2021 (GLOBE NEWSWIRE) — DunAn Microstaq, Inc. (DMQ), a MEMS technology company that innovates flow control solutions primarily for the HVAC, refrigeration and automotive industries, expands its Modular Silicon Expansion Valve (MSEV) product family for cooling capacities from sub 1 to 50 tons in R-410A and comparable low GWP replacement refrigerants.

The product family is comprised of three capacity ranges: Modular Silicon Expansion Valve (1 to 8 tons), High-Capacity Modular Silicon Expansion Valve (10 to 25 tons) and Very High-Capacity Modular Silicon Expansion Valve (26 to 50 tons). The valves are the fastest responding refrigerant expansion valves in the HVAC/R industry that makes them suitable for dynamic thermal load changes in HVAC/R systems. The fast response is achieved by the embedded ultra-fast MEMS based piloting silQflo® Silicon Servo Valve (SSV). The 1-ton MSEV model can be used for a refrigeration system with cooling capacity requirement anywhere between 1000 BTU/h to 12000 BTU/h.

The valves are autonomously controlled by DMQ’s palm sized Universal SuperHeat Controller (USHC). The control algorithm is designed and qualified to work with single-stage, dual-stage and variable speed compressors with embedded intelligent control algorithms.

The USHC is a smart controller that consists of an integrated pressure sensor, an external temperature sensor and a Pulse-Width-Modulation (PWM) driver which can be read over a RS485 communication BUS using MODBUS RTU protocol. It is preprogrammed with the most common ASHARAE A1 as well as several A2 safety class refrigerants thereby offering HVAC/R manufacturers a plug-and-play solution. This capability reduces engineering time and enables manufacturers to qualify and deploy their products to the market in a short time frame.

Alternatively, the USHC can also be used as a digital pressure & temperature sensor (one integrated pressure and two external temperature sensors) with programmable PWM duty cycle and frequency for 12V/24V third party actuators or LED lighting controls (max current 1.5A).

The HVAC/R systems can be integrated to the DMQ’s Intelligent HVAC-R cloud solution that can communicate with the USHC over cloud infrastructure. An Internet of Things (IoT) solution monitors and reports the performance of the system in the field to the end user remotely. The DMQ solution brings system performance data right to the end user hand via mobile platform.

The MSEV and USHC are qualified for air handling units, air-source and water-source heat pumps, chillers, self-contained refrigeration systems and refrigerant based data center cooling systems.

About DunAn Microstaq

DunAn Microstaq, Inc. (DMQ) is a MEMS technology company dedicated to advancing flow control solutions primarily for the HVAC, refrigeration and automotive industries. Their pioneering work in microelectromechanical systems technology, understanding of customers’ needs and experiences translate into benefits that go far beyond flow control. DMQ solutions accelerate product development cycles, cut across design challenges, create warehousing efficiencies and reduce deployment time. With a core technology so versatile, DMQ can package its devices along with the sensing and controls software for custom applications to fit a multitude of markets. For more information about DMQ products, email [email protected] or visit www.dmq-us.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/095f68ef-64eb-4354-9325-9291496a56da

Media Contact: 
Dhaman Besarla
Systems & Applications Engineering Manager
[email protected]

NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) — SLR Senior Investment Corp. (the “Company”) (NASDAQ: SUNS) declared a distribution of $0.10 per share for the month of April 2021. The distribution is payable on April 30, 2021 to stockholders of record as of April 21, 2021. The specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year.

ABOUT SLR SENIOR INVESTMENT CORP.

SLR Senior Investment Corp. is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. A specialty finance company with expertise in several niche markets, the Company generally invests directly and indirectly in leveraged, U. S. middle market companies primarily in the form of cash flow senior secured loans, including first lien loans, and asset-based loans collateralized on a first lien basis primarily by current assets.

FORWARD-LOOKING STATEMENTS

Statements included herein may constitute “forward-looking statements,” which relate to future events or our future performance or financial condition. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties, including the impact of COVID-19 and related changes in base interest rates and significant market volatility on our business, our portfolio companies, our industry and the global economy. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission. SLR Senior Investment Corp. undertakes no duty to update any forward-looking statements made herein, unless required to do so by law.

Contact:
SLR Senior Investment Corp.
Investor Relations
646-308-8770

VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has appointed Dr. Steven L. Wolf, a global expert in the field of Physical Therapy & Rehabilitation Medicine, as a consultant for its clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”).

Dr. Wolf, PT, PhD, FAPTA, is a professor in the Department of Rehabilitation Medicine, Emory University School of Medicine, where he explores novel interventions to improve extremity use in patients with stroke as well as mechanisms of cortical reorganization and inter-joint coordination associated with such changes. He is a world expert in physical therapy, a prolific and innovative researcher and leader who has made seminal contributions to patient care, and a highly sought-after lecturer and teacher who has been a valued mentor to students, residents and faculty. Dr. Wolf’s research has been widely disseminated via more than 300 publications. He has also authored or co-authored nine books that have become major pillars in the fields of physical therapy and rehabilitation medicine. Dr. Wolf has additionally made numerous appearances on National Public Radio and CNN, as well as multiple other media outlets as a subject expert commentator.

Dr. Wolf joins a distinguished group of scientists, researchers and clinicians who are working to help guide Algernon as it develops its DMT stroke clinical research program. His role will be to specifically assist with the investigation of DMT in the rehabilitation of patients that have suffered some form of deficit as a result of a stroke.

“We welcome Dr. Wolf to the Algernon team and look forward to his overall contributions and specifically his guidance on the design of our Phase 2 clinical study of DMT for stroke patients who are suffering from the effects of a stroke,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “If DMT can help rewire the brain after an ischemic stroke, as indicated in a recent animal study, perhaps it can help people recover more quickly and reduce some of the serious long-term effects that result.”

About Algernon Pharmaceuticals Inc. 

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701

[email protected] 
[email protected] 
www.algernonpharmaceuticals.com. 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. 

SEATTLE, April 06, 2021 (GLOBE NEWSWIRE) — Porch Group, Inc. (“Porch” or “the Company”) (NASDAQ: PRCH), a leading vertical software company reinventing the home services industry, successfully completed its previously announced acquisition of Homeowners of America (HOA), making Porch one of the largest Insurance Technology (InsurTech) companies.

HOA is a Managing General Agent and insurance carrier hybrid with high margins and a capital efficient reinsurance strategy which limits retained risk. HOA primarily operates in six states, including Texas, Arizona, North Carolina, South Carolina, Virginia, and Georgia. The company was founded in 2006 in Texas, a $10 billion homeowners insurance market, and was the 12^th largest home insurer in Texas in 2019. HOA is licensed to operate in 31 states, positioning it for nationwide expansion as part of Porch.

Porch acquired HOA for approximately $100 million, subject to customary purchase price adjustments, of which approximately $21.7 million is payable in Porch common stock.

“With HOA’s experienced management team and scale of effective insurance operations, combined with Porch’s homebuyer access and unique property data, we are positioned to scale into our InsurTech ambitions,” said Matt Ehrlichman, Porch founder, chairman and CEO. “We are looking to immediately provide value to current HOA agents and customers through our technology platform and expanded offerings to be more than just an insurance carrier, but the partner for the home. We expect HOA’s fit within our unique vertical software platform will provide rapid, scalable, and profitable growth. The InsurTech space is nascent, and this acquisition demonstrates our commitment to industry leadership.”

With the acquisition, Porch seeks to create efficient growth with reduced customer acquisition cost through the homebuyers accessed through its vertical software platform, proprietary property data collection and HOA’s current licensure in 31 states. Porch plans to expand HOA’s Insurtech footprint nationwide through its own insurance offering and HOA’s existing independent agent distribution channels.

Combining Porch’s vast access to homebuyers and unique property data with HOA’s strong pricing and claims experience, Porch believes it can become one of the largest InsurTech companies with significant advantages to driving rapid, long-term growth. For the full year 2021, the Company expects over $270 million of pro forma gross written premium between HOA and Porch’s existing insurance agency.

Agents and customers currently using HOA services should expect enhanced product offering and expanded opportunities through the Porch vertical technology systems and data.

About

Porch

Group

Seattle-based Porch Group, the vertical software platform for the home, provides software and services to more than 11,150 home services companies such as home inspectors, moving companies, real estate agencies, utility companies, and warranty companies. Through these relationships and its multiple brands, Porch provides a moving concierge service to homebuyers, helping them save time and make better decisions on critical services, including insurance, moving,security, TV/internet, home repair and improvement, and more. To learn more about Porch, visit porchgroup.com or porch.com.

Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Porch’s future financial or operating performance. For example, projections of future revenue, and other metrics, business strategy and plans, and anticipated impacts from pending or completed acquisitions, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.   These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Porch and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of Porch’s December 2020 business combination (the “Merger”) with PropTech Acquisition Corporation (“PropTech”), which may be affected by, among other things, competition and the ability of the combined company to grow and manage growth profitably, maintain key commercial relationships and retain its management and key employees; (2) expansion plans and opportunities, including future and pending acquisitions or additional business combinations; (3) costs related to the Merger and being a public company; (4) litigation, complaints, and/or adverse publicity; (5) the impact of changes in consumer spending patterns, consumer preferences, local, regional and national economic conditions, crime, weather, demographic trends and employee availability; (6) privacy and data protection laws, privacy or data breaches, or the loss of data; (7) the impact of the COVID-19 pandemic and its effect on the business and financial conditions of Porch; and (8) other risks and uncertainties described in Porch’s filings with the Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. 

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Porch does not undertake any duty to update these forward-looking statements, except as may be required by law.

Porch Press contact:

Jordan Schmidt
Gateway Group
(949) 386-6332
[email protected]

Porch Investor Relations contact:

Cody Slach, Matt Glover
Gateway Group
(949) 574-3860
[email protected]

MONTREAL, April 06, 2021 (GLOBE NEWSWIRE) — TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that it will hold its Annual Meeting of shareholders on Tuesday, April 27, 2021 at 1:30 p.m. (Eastern Time) at the Company’s head office, 8801 Trans-Canada Highway, Suite 500, Saint-Laurent, Quebec. The meeting will also be available by way of telephone conference call. The dial-in number for the meeting is 877-223-4471. In light of the COVID-19 pandemic, shareholders are asked to participate in the meeting by telephone and to vote their shares prior to the meeting by returning their proxy form or voting instruction form, voting online or using the toll-free telephone number set out on the proxy or voting instruction form. During the telephone meeting, shareholders will be able to ask questions but will not be able to vote. In light of government directives relating to COVID-19, attendance for the meeting at the Company’s head office will be strictly limited to the Company’s registered shareholders and duly-appointed proxyholders.

Also on Tuesday, April 27, the Company will issue its financial results for the first quarter ended March 31, 2021 via news release after the market close. The Company will then hold a conference call for analysts and investors with Alain Bédard, Chairman, President and Chief Executive Officer, on Wednesday, April 28 at 8:30 a.m. Eastern Time, to discuss the quarterly results. Business media are also invited to listen to the call. Please dial in 10 minutes prior to the start of the call.

Details of quarterly results conference call:
Date: Wednesday, April 28, 2021
Time: 8:30 a.m. Eastern Time
Call-in number: 877-223-4471

A recording of the call will be available until midnight, May 12, 2021, by dialing 800-585-8367 or 416-621-4642 and entering passcode 4780937.

Finally, TFI International Inc.’s 2020 Annual Report is now available on the Company’s website at:
www.tfiintl.com/en/presentations-and-reports/.

ABOUT TFI INTERNATIONAL

TFI International Inc. is a North American leader in the transportation and logistics industry, operating across the United States, Canada and Mexico through its subsidiaries. TFI International creates value for shareholders by identifying strategic acquisitions and managing a growing network of wholly-owned operating subsidiaries. Under the TFI International umbrella, companies benefit from financial and operational resources to build their businesses and increase their efficiency. TFI International companies service the following segments:

• Package and Courier;
• Less-Than-Truckload;
• Truckload;
• Logistics.

TFI International Inc. is publicly traded on the New York Stock Exchange and the Toronto Stock Exchange under the symbol TFII. For more information, visit www.tfiintl.com/.

For further information:

Alain Bédard
Chairman, President and CEO
TFI International Inc.
647-729-4079
[email protected]

AVENTURA, Fla., April 06, 2021 (GLOBE NEWSWIRE) — Life Clips, Inc. (OTC Pink: LCLP) (the “Company”), today announced that it has closed the acquisition of Cognitive Apps Software Solutions Inc. (Cognitive Apps), a developer of artificial intelligence (AI) applications for the healthcare industry and psychedelic research.

Cognitive Apps provides an AI powered mental health analytics platform empowering businesses to measure, understand, and improve the mental well-being of their employees, patients or customers. The Cognitive Apps solution is driven to achieve the Three Pillars: improved diagnostic outcomes, better and more personalized care for individuals, and to decrease the overall costs and time for the care. An individual only needs to record their voice on a handset, iPad, or tablet. The Cognitive Apps assessment is designed to be administered as often as daily, in order to provide a more granular picture of changes in mental health over time. As a result, the Cognitive apps assessment can be routinely completed to monitor mental health and track variables that might be impacted by treatment.

Dr. Manideep Gopishetty, CEO and Co-founder of Cognitive Apps, said, “Our technology is designed to measure very tiny changes in individuals mental health and is able to identify the risk factors behind it by collecting data in two forms, both voice and text. Based on the assessment, our company also deploys interactive content and chat bots for personalized care of the individuals. Overall AI is not an intruder but a multi-talented, non-biased personalized assistant which can improve the care, treatment outcomes and lifestyle of patients.”

With the acquisition, Life Clips gains access to Cognitive Apps’ intellectual property, including AI enabled speech-based technology, and its research and development team. Life Clips will further develop Cognitive Apps’ technology for use in the development and testing of psychedelics and other molecules related to mental health indications for the treatment of various mental health disorders.

Robert Grinberg, CEO and Director of Life Clips, said, “The acquisition of Cognitive Apps marks the first step in growth and expansion strategy of Life Clips. As we continue to move forward, we maintain a positive business outlook focused on achieving revenue growth, profitability and value creation for our shareholders. We expect this transaction to serve as a launchpad for Life Clips to broaden operations and expand into multiple markets.” Mr. Grinberg continued, “We are enthusiastic, after months of tough negotiations and careful due diligence, to move forward with the acquisition of Cognitive Apps. As well, we are truly so pleased to work closely with Dr. Manideep Gopishetty, who will bring a tremendous amount of knowledge to the team we plan to assemble at Life Clips.”

Cognitive Apps delivers a comprehensive approach to well-being, supporting the whole person. Cognitive apps currently has partnerships with Ehave (OTC: EHVVF), Mycotopia (OTC: TWGL), Welmind EMR, Betterhelp, Belshare, and Movefit.

Visit our corporate website at www.lifeclips.com.

About Life Clips, Inc.

Life Clips is the parent company of Cognitive Apps Software Solutions Inc. and distributes single-use and cordless batteries under the Mobeego brand for use in cellular phones and other mobile devices. Cognitive Apps is an AI-Powered mental health analytics platform that empowers businesses to measure, understand, and improve mental well-being of their employees, patients and customers. Drug development for mental health disorders and other cognitive impairments is hampered by the ability to identify at risk groups before the onset of clinically significant symptoms, as well as continuous assessments on the progress made by the participants. Cognitive Apps is addressing this problem by pioneering a speech-based AI technology which could help accurately predict risk for various types of depression and mood and anxiety-based disorders years before a clinical diagnosis is obtained. Our technology can help detect and monitor subtle changes in mental state by assessing individuals more frequently and more objectively than the assessments used today. Cognitive apps currently has partnerships with Ehave, Mycotopia, Welmind EMR, Betterhelp, Belshare, and Movefit.

Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

Contact: LifeClips, Inc.
Gabriel P. Rodriguez
Investor Relations: (623) 261-9046
Email: [email protected]